Living Conditions After Non-Hodgkin's Lymphoma in France

NCT ID: NCT05583318

Last Updated: 2025-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1570 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2023-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an innovative project, allowing to study for the first time the long-term living conditions of patients after diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) from population data in France. Patients will be selected from the three specialized hematology registries in France: Côte-d'Or, Gironde and Basse-Normandie.

This is also one of the first studies to look at epidemiological indicators of net survival after diagnosis of follicular lymphoma and diffuse large B-cell lymphoma, adjusted for clinical factors such as disease stage, therapeutic management, and comorbidities, apart from the standard adjustment factors of age, sex, and time of diagnosis in real life. In addition, the proportion of cured patients will be estimated.

For component 1, this will be the survival analysis on the initial data. For part 2, questionnaires will be sent out followed by a follow-up if necessary one month after the mailing. There is no physical interview nor any specific biological or imaging examination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-hodgkin's Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1: Patients diagnosed with non-Hodgkin's lymphoma

Diagnosis period 2010-2018, from the hematological malignancy registries of Côte-d'Or, Gironde, Basse-Normandie

Data collection

Intervention Type OTHER

Data from hematological malignancy registries

Part 2: Patients diagnosed with live non-Hodgkin's lymphoma after vital status update

Update of vital status in December 2022

Questionnaires

Intervention Type OTHER

9 questionnaires were sent out:

1. QLQ-C30 and SF-12 Quality of Life Questionnaire.
2. Oral quality of life questionnaire QLQ-OH15
3. Sexuality questionnaire SHQ-C22
4. Anxiety and depression questionnaire HADS,
5. Rosenberg Self-Esteem Questionnaire
6. RNLI Reintegration to Normal Life Questionnaire
7. Social Support Questionnaire SSQ6,
8. Socio-economic status questionnaire EPICES,
9. Complementary questionnaire collecting data on socio-professional status.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Data from hematological malignancy registries

Intervention Type OTHER

Questionnaires

9 questionnaires were sent out:

1. QLQ-C30 and SF-12 Quality of Life Questionnaire.
2. Oral quality of life questionnaire QLQ-OH15
3. Sexuality questionnaire SHQ-C22
4. Anxiety and depression questionnaire HADS,
5. Rosenberg Self-Esteem Questionnaire
6. RNLI Reintegration to Normal Life Questionnaire
7. Social Support Questionnaire SSQ6,
8. Socio-economic status questionnaire EPICES,
9. Complementary questionnaire collecting data on socio-professional status.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis period 2010-2018, according to the 2008 WHO ICD-O-3 classification, from the hematological malignancy registries of Côte-d'Or, Gironde, Basse-Normandie
* Patients with a diagnosis of follicular lymphoma (9690/3, 9691/3, 9695/3, 9698/3, 9597/3)
* Patients with a diagnosis of diffuse large B-cell lymphoma (9678/3, 9679/3, 9680/3, 9684/3, 9688/3, 9712/3, 9735/3, 9737/3, 9738/3)
* For Part 2: Individuals alive at the date of vital status update


* Other forms of malignant hemopathies at diagnosis,
* Minors.

Exclusion Criteria

* Person under a legal protection measure (curatorship, guardianship)
* Person under a legal protection measure (guardianship, tutorship)
* Pregnant, parturient or breastfeeding women
* Major incapable or unable to express his consent
* Person who did not return the questionnaires following the 1-month follow-up, or patient who expressed refusal to participate.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Dijon Bourgogne

Dijon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MAYNADIE 2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.